CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

8630	Companies
143980	Keywords
79657	Articles
76974	Press releases

Home
Companies
CureVac

BRIEF

published on 04/10/2025 at 13:17, 17 days 2 hours ago

CureVac's 2024 Financial Results and Strategic Developments

Financial Results MRNA Technology Patent Litigation GSK Collaboration Oncology Programs
PRESS RELEASE

published on 04/10/2025 at 13:12, 17 days 2 hours ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
CureVac announces financial results for the fourth quarter and full-year 2024 and provides a business update, including milestone achievements, financial discipline, and litigation updates

Financial Results Business Update Intellectual Property CureVac Precision Immunotherapy
BRIEF

published on 04/08/2025 at 13:05, 19 days 2 hours ago

CureVac Announces Financial Results and Business Update for 2024

Financial Results Conference Call Business Update MRNA Technology CureVac
PRESS RELEASE

published on 04/08/2025 at 13:00, 19 days 2 hours ago

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025. Conference call and webcast scheduled at 3 p.m. CET / 9 a.m. EST

Financial Results Conference Call Business Update MRNA Technology CureVac
BRIEF

published on 04/07/2025 at 13:05, 20 days 2 hours ago

CureVac Advances mRNA Immunotherapy for Lung Cancer

FDA Clearance Clinical Trial CureVac MRNA Immunotherapy SqNSCLC
PRESS RELEASE

published on 04/07/2025 at 13:00, 20 days 2 hours ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
CureVac receives U.S. FDA clearance for phase 1 trial of mRNA immunotherapy in squamous NSCLC, a novel approach combining precision therapy with pembrolizumab

FDA Clearance CureVac MRNA Immunotherapy Squamous NSCLC Precision Therapy
BRIEF

published on 03/27/2025 at 21:10, 30 days 18 hours ago

CureVac Secures Patent Win Against BioNTech

BioNTech MRNA Technology CureVac Patent Litigation European Patent Office
PRESS RELEASE

published on 03/27/2025 at 21:05, 30 days 18 hours ago

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
CureVac receives positive validity decision from European Patent Office in litigation against BioNTech SE regarding mRNA patent

BioNTech SE CureVac Patent Litigation European Patent Office MRNA Patent
BRIEF

published on 02/18/2025 at 13:08, 2 months 9 days ago

CureVac Recognized as a Global Innovator by LexisNexis

MRNA Technology Patent Portfolio CureVac Health Innovation Top Innovator
PRESS RELEASE

published on 02/18/2025 at 13:03, 2 months 9 days ago

CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators
CureVac recognized as Top 100 Global Innovator by LexisNexis for third year in a row due to its extensive mRNA technology patent portfolio. Company leads in mRNA science

MRNA Technology Patent Portfolio CureVac Global Innovator LexisNexis

1 2 ... 9

Accesswire

Published on 04/26/2025 at 02:00, 1 day 13 hours ago

Battery X Metals Announces Strategic Agreement to Advance Artificial Intelligence-Driven Exploration of Critical Battery Metals in Nevada, USA
Published on 04/25/2025 at 23:30, 1 day 16 hours ago

AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Published on 04/25/2025 at 23:01, 1 day 16 hours ago

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2024
Published on 04/25/2025 at 23:00, 1 day 16 hours ago

AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Published on 04/25/2025 at 22:15, 1 day 17 hours ago

Grande Portage Resources Announces Extension of Expiry Date for Warrants

View all ACCESSWIRE

EQS Group

Published on 04/25/2025 at 22:47, 1 day 17 hours ago

DEAG achieves new revenue level in “transformation year” 2024 – Strategic investments and strong start to the year create basis for future sustainable growth
Published on 04/25/2025 at 20:30, 1 day 19 hours ago

EQS-Adhoc: Nagarro SE: Confirms 2024 guidance and dividend, postpones publication for full-year results
Published on 04/25/2025 at 18:44, 1 day 21 hours ago

Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 04/25/2025 at 18:31, 1 day 21 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/25/2025 at 18:30, 1 day 21 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 04/25/2025 at 18:16, 1 day 21 hours ago

PR_Carrefour Brazil_25042025
Published on 04/25/2025 at 18:05, 1 day 21 hours ago

Louis Hachette Group - 2025 First-quarter revenue
Published on 04/25/2025 at 18:00, 1 day 21 hours ago

Availability of the 2024 universal registration document
Published on 04/25/2025 at 18:00, 1 day 21 hours ago

Postponement of the publication of the annual financial statements
Published on 04/25/2025 at 17:45, 1 day 22 hours ago

LANSON-BCC: GENERAL SHAREHOLDERS’ MEETING ON APRIL 25, 2025 - DIVIDEND: €0.90 PER SHARE

View all LES ECHOS COMFI WIRE